Liver failure is one of the most deadly, prevalent, and costly diseases worldwide. Non-bioartificial liver support systems (NBALs) have been shown to be effective in improving the clinical symptoms and laboratory parameters of patients with liver failure. The main aim of this large case series analysis was to investigate the status of NBALs and their effectiveness in improving survival in liver-failure patients.
Methods
In this retrospective study, 460 patients with liver failure who received NBAL treatment in addition to conventional medications were compared with 422 patients who were treated with conventional medications alone. Kaplan-Meier and life table analyses were used to estimate survival rates.
Results
Clinical outcomes were improved after NBAL treatment. The 30-day survival rates of subacute liver failure (SALF) patients were 63% among those who received NBALs and 21% among those who did not receive NBALs (p<0.01). Similarly, the 30-day survival rate of acute-on-chronic liver failure (ACLF) patients who received NBALs was 47%, significantly higher than that of the non-NBAL patients (p<0.05). The survival rates of ACLF patients with low Model for End-Stage Liver Disease (MELD) scores (MELD≤20) were 64% and 40% among whom received NBALs and those who did not, respectively (p<0.01).
Conclusions
NBAL treatment is helpful to improve the survival of patients with ALF, SALF or ACLF. ACLF patients with lower MELD scores showed improved outcomes relative to those with higher MELD scores.
Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association; Severe Liver Diseases and Artificial Liver Group, Chinese Society of Hepatology, Chinese Medical Association.[Diagnostic and treatment guidelines for liver failure] [Article in Chinese].Zhonghua Gan Zang Bing Za Zhi.2006; 14(9): 643–646.
2.
OstapowiczG., FontanaR.J., SchiødtF.V.; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States.Ann Intern Med.2002; 137(12): 947–954.
3.
SchiodtF.V., AtillasoyE., ShakilA.O.. Etiology and outcome for 295 patients with acute liver failure in the United States.Liver Transpl Surg.1999; 5(1): 29–34.
4.
LeeW.M.. Acute liver failure in the United States.Semin Liver Dis.2003; 23(3): 217–226.
5.
KatoonizadehA., LalemanW., VerslypeC.. Early features of acute-on-chronic alcoholic liver failure: a prospective cohort study.Gut.2010; 59(11): 1561–1569.
6.
LiL.J., WangZ.H., YeW.J.. Artificial liver.Hangzou: ZheJiang University Press; 2012.
7.
LingQ., XuX., WeiQ.. Downgrading MELD improves the outcomes after liver transplantation in patients with acute-on-chronic hepatitis B liver failure.PLoS One.2012; 7(1): e30322.
8.
DuW.B., LiL.J., HuangJ.R.. Effects of artificial liver support system on patients with acute or chronic liver failure.Transplant Proc.2005; 37(10): 4359–4364.
9.
Artificial Liver Group Chinese Association of Infectious and Parasitic Diseases.[Operating guide for artificial liver support system] [Article in Chinese].Zhonghua Gan Zang Bing Za Zhi.2002; 10(5): 329–332.
10.
van den BesselaarA.M.. Precision and accuracy of the international normalized ratio in oral anticoagulant control.Haemostasis.1996; 26(Suppl 4): 248–265.
11.
FerenciP., LockwoodA., MullenK., TarterR., WeissenbornK., BleiA.T.. Hepatic encephalopathy–definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.Hepatology.2002; 35(3): 716–721.
12.
ConnH.O., LeevyC.M., VlahcevicZ.R.. Comparison of lactulose and neomycin in the treatment of chronic portal- systemic encephalopathy. A double blind controlled trial.Gastroenterology.1977; 72(4 Pt 1): 573–583.
13.
CoxD.R.. Regression models and life-tables.J R Stat Soc Series B Stat Methodol1972; 34: 187–220.
14.
ShakilA.O., KramerD., MazariegosG.V., FungJ.J., RakelaJ.. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria.Liver Transpl.2000; 6(2): 163–169.
ChenY.S., WuZ.W., HeJ.Q.. The curative effect of ALSS on 1-month mortality in AoCLF patients after 72 to 120 hours.Int J Artif Organs.2007; 30(10): 906–914.
17.
YoshibaM., InoueK., SekiyamaK., KohI.. Favorable effect of new artificial liver support on survival of patients with fulminant hepatic failure.Artif Organs.1996; 20(11): 1169–1172.
18.
StutchfieldB.M., SimpsonK., WigmoreS.J.. Systematic review and meta-analysis of survival following extracorporeal liver support.Br J Surg.2011; 98(5): 623–631.
19.
MaoW., YeB., LinS., FuY., ChenY., ChenY.. Prediction value of model for end-stage liver disease scoring system on prognosis in the acute on chronic liver failure patients with plasma exchange treatment.ASAIO J.2010; 56(5): 475–478.
20.
YuJ.W., SunL.J., ZhaoY.H., LiS.C.. Prediction value of model for end-stage liver disease scoring system on prognosis in patients with acute-on-chronic hepatitis B liver failure after plasma exchange and lamivudine treatment.J Gastroenterol Hepatol.2008; 23(8 Pt 1): 1242–1249.
21.
QianY., LanjuanL., JianrongH.. Study of severe hepatitis treated with a hybrid artificial liver support system.Int J Artif Organs.2003; 26(6): 507–513.
22.
LiL.J., YangQ., HuangJ.R., XuX.W., ChenY.M., FuS.Z.. Effect of artificial liver support system on patients with severe viral hepatitis: a study of four hundred cases.World J Gastroenterol.2004; 10(20): 2984–2988.
23.
KjaergardL.L., LiuJ., Als-NielsenB., GluudC.. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review.JAMA.2003; 289(2): 217–222.
24.
VaidA., ChweichH., BalkE.M., JaberB.L.. Molecular adsorbent recirculating system as artificial support therapy for liver failure: a meta-analysis.ASAIO J.2012; 58(1): 51–59.
25.
KribbenA., GerkenG., HaagS.; HELIOS Study Group. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure.Gastroenterology.2012; 142(4): 782–789, e3.
ReubenA., KochD.G., LeeW.M.; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study.Hepatology.2010; 52(6): 2065–2076.
28.
LarsonA.M., PolsonJ., FontanaR.J.. Acetaminophen-induced acute liver failure: Results of a United States multicenter, prospective study.Hepatology.2005; 42: 1364–1372.
29.
LeeW.M.. Acetaminophen and the U.S. Acute Liver Failure Study Group: lowering the risks of hepatic failure.Hepatology.2004; 40(1): 6–9.
30.
LeeW.M., SquiresR.H.Jr., NybergS.L., DooE., HoofnagleJ.H.. Acute liver failure: Summary of a workshop.Hepatology.2008; 47(4): 1401–1415.
31.
YangS.G., WangB., ChenP.. Effectiveness of HBV vaccination in infants and prediction of HBV prevalence trend under new vaccination plan: findings of a large-scale investigation.PLoS One.2012; 7(10): e47808.
32.
PolsonJ., LeeWM; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure.Hepatology.2005; 41(5): 1179–1197.
33.
SarinS.K., KumarA., AlmeidaJ.A.. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).Hepatol Int.2009; 3(1): 269–282.
